merck & co. inc. (6MK:Frankfurt)
Transactions by MERCK & CO. INC. (6MK) in the last 6 months
Merck & Co. Inc. (NYSE:MRK) agreed to acquire eCardio Diagnostics, LLC from Sequoia Capital on August 22, 2014. The deal has received early termination notice from Federal Trade Commission.
Merck & Co. Inc. (NYSE:MRK) entered into a definitive agreement to acquire Idenix Pharmaceuticals Inc. (NasdaqGS:IDIX) from T. Rowe Price Associates, Inc., Nomura International plc, Brookside Capital Management, LLC, The Baupost Group, LLC and other shareholders for $3.84 billion in cash on June 8, 2014. Under the terms of the agreement, Merck will pay $24.5 per share. Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire ...
MPM BioVentures I, L.P.
Nomura International plc
Novartis Pharma AG
Novartis Venture Funds
T. Rowe Price Associates, Inc.
The Baupost Group, LLC
Santen Pharmaceutical Co. Ltd. (TSE:4536) entered into an agreement to acquire ophthalmology assets in Japan and key markets in Europe and Asia Pacific from Merck & Co. Inc. (NYSE:MRK) for $600 million on May 13, 2014. Under the terms, Santen Pharmaceutical Co. Ltd. will make an upfront payment of approximately $600 million and additional payments based on defined sales milestones. Santen intends to fund the acquisition with a combination of cash on hand and bank loans. ...
KBI Biopharma Inc. acquired microbial process development and manufacturing operations in Boulder, Colorodo from Merck & Co. Inc. (NYSE:MRK) on May 13, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck & Co. Inc. as well as to third-party customers. All 30 Merck employees in Boulder have been retained by KBI. Fintan Walton of PharmaVentures Ltd. acted as financial advisor to Merck & Co.
Bayer AG (DB:BAYN) signed an agreement to acquire the consumer care business of Merck & Co., Inc. (NYSE:MRK) for $14.2 billion in cash on May 5, 2014. The consideration is inclusive of assumption of liabilities and payment of debt at closing. Bayer will acquire the business as part of an auction. Under the terms of the agreement, Bayer AG will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. Concurrent ...
|Bayer AG||€101.51 EUR||-1.15|
|GlaxoSmithKline PLC||1,463 GBp||+15.50|
|Pfizer Inc||$29.49 USD||+0.28|
|Roche Holding AG||SFr.268.20 CHF||-1.20|
|View Industry Companies|